ReviewFrontiers in immunology2025
cGAS-STING signaling: a therapeutic target in inflammatory bowel disease and related colorectal cancer.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Nanoparticle delivery of Chinese medicine monomers for remodeling the colorectal cancer immune microenvironment.Discover nano · 2026Review
- The Significance of cGAS-STING Signaling in Response to Oncogenic Viruses.Cell biochemistry and function · 2026Review
- Editorial: Checkpoint immunotherapy: reshaping the landscape of gastrointestinal cancer treatment, volume II.Frontiers in immunology · 2026Article
- The mitochondrial DNA-cGAS-STING axis in colorectal cancer: a focused review of context-dependent roles and therapeutic opportunities.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway is a critical mechanism of DNA sensing in innate immunity. Activation of this pathway can induce the production of interferons and proinflammatory cytokines. In the intestine, this pathway exhibits bidirectional regulatory properties, with appropriate activation maintaining homeostasis and inhibiting tumorigenesis, while excessive activation leads to inflammatory responses. A thorough exploration of the molecular mechanisms and regulatory networks of the cGAS-STING signaling pathway offers a significant theoretical foundation and potential treatment targets for developing novel strategies to treat intestinal diseases. This review summarizes the most recent developments on the function of the cGAS-STING regulatory pathway in colorectal tumors and inflammatory bowel disease. It discusses targeted therapeutic approaches that interfere with this pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.